Karyopharm Therapeutics Inc Asset Resilience Ratio
Karyopharm Therapeutics Inc asset resilience ratio. Karyopharm Therapeutics Inc (KPTI) has an Asset Resilience Ratio of 9.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Karyopharm Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Karyopharm Therapeutics Inc (2013–2025)
Asset resilience ratio of Karyopharm Therapeutics Inc from 2013 to 2025. This chart shows how Karyopharm Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Karyopharm Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Karyopharm Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Karyopharm Therapeutics Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.12 Million | 9.1% |
| Total Liquid Assets | $10.12 Million | 9.10% |
Asset Resilience Insights
- Limited Liquidity: Karyopharm Therapeutics Inc maintains only 9.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Karyopharm Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Karyopharm Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GT Biopharma Inc
NASDAQ:GTBP |
Biotechnology | 0.00% |
|
Kura Oncology Inc
NASDAQ:KURA |
Biotechnology | 76.35% |
|
Sprint Bioscience AB
ST:SPRINT |
Biotechnology | 77.81% |
|
Herantis Pharma Oyj
HE:HRTIS |
Biotechnology | 89.18% |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258 |
Biotechnology | 45.84% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Argenica Therapeutics Ltd
AU:AGN |
Biotechnology | 0.52% |
Karyopharm Therapeutics Inc Asset Resilience Ratio by Year (2013–2025)
Karyopharm Therapeutics Inc asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Karyopharm Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.96% | $3.20 Million | $108.42 Million | -25.17pp |
| 2024-12-31 | 28.12% | $46.24 Million | $164.42 Million | -29.78pp |
| 2023-12-31 | 57.90% | $139.21 Million | $240.44 Million | +18.04pp |
| 2022-12-31 | 39.86% | $142.78 Million | $358.17 Million | +27.37pp |
| 2021-12-31 | 12.50% | $38.16 Million | $305.31 Million | -39.67pp |
| 2020-12-31 | 52.17% | $163.32 Million | $313.05 Million | +7.05pp |
| 2019-12-31 | 45.12% | $133.10 Million | $294.96 Million | -16.48pp |
| 2018-12-31 | 61.60% | $210.18 Million | $341.19 Million | +18.63pp |
| 2017-12-31 | 42.97% | $77.47 Million | $180.29 Million | -1.32pp |
| 2016-12-31 | 44.29% | $79.89 Million | $180.38 Million | -10.15pp |
| 2015-12-31 | 54.43% | $117.28 Million | $215.44 Million | +29.42pp |
| 2014-12-31 | 25.01% | $55.12 Million | $220.34 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $158.23 Million | -- |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more